M2 Europharma articles

Recent articles from M2 Europharma

GlaxoSmithKline teams with Biovitrum on obesity drug development.(Brief Article)
October 30, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD UK-based pharmaceutical firm GlaxoSmithKline Plc has signed a collaboration agreement with Swedish biotechnology company Biovitrum AB. Under the agreement the two companies plan to develop and commercialise Biovitrum's 5HT2C...

Shire and Berna Biotech form vaccine agreement.(Shire Pharmaceuticals Group Plc, Berna Biotech AG)(Brief Article)
October 31, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD UK-based Shire Pharmaceuticals Group Plc has entered into a vaccine agreement with Switzerland's Berna Biotech AG. Under the agreement, Shire will manufacture and supply its Flurival influenza vaccine to Berna Biotech for sale in...

Genmab launches HuMax-CD20 programme.(Genmab A/S developing antibodies to treat cancer)(Brief Article)
October 31, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD Danish biotechnology company Genmab A/S has announced the start of its HuMax-CD20 programme, with the initial focus on the treatment of cancer. The antibodies being developed under the programme target the CD20 antigen on B-cells,...

Aventis reveals positive results from Arava studies.(Brief Article)
October 31, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD Franco-German drug group Aventis SA has revealed that two studies of its Arava drug indicated that the product was safe and effective in treating rheumatoid arthritis. The first study showed that when given alone and in combination,...

Trial shows AstraZeneca's thrombosis drug Exanta to be superior to rival.(Brief Article)
October 31, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD Anglo-Swedish drug group AstraZeneca Plc has claimed that a trial of its thrombosis drug Exanta found it to be superior to Aventis SA's Lovenox. According to AstraZeneca, the EXPRESS phase III clinical trial with Exanta (oral...